Inclusion Criteria:

- Confirmed diagnosis of multiple myeloma.

- Measurable disease, according to the International Myeloma Working Group criteria.

- ECOG performance status 0, 1 or 2.

- Patients must have received prior treatment for MM and have relapsed or progressed on
prior therapy; no limit on number of prior treatment regimens, but prior treatment
must be completed 2 weeks prior to registration. Prior exposure to Bortezomib is not
an exclusion criteria as long as patients did not progress or relapse while receiving
or within 3 months of completing trt with bortezomib

- Prior radiation, completed at least 4 weeks prior to registration, is permitted.

- Adequate marrow reserve, liver and renal function

Exclusion Criteria:

- patients with a history of other malignancies, except: adequately treated nonmelanoma
skin cancer, curatively treated in-situ cancer of the cervix, prostate cancer with
stable PSA for > 3 years, or other solid tumours curatively treated with no evidence
of disease for > 5 years.

- Patients with preexisting grade 2 (or higher) sensory neuropathy or grade 1 sensory
neuropathy with neuropathic pain.

- Pregnant or lactating women

- Patients receiving concurrent treatment with other anti-cancer therapy any other
investigational agents.

- Active or uncontrolled infections

- Patient with known documented congenital or acquired risk factor for thromboembolic
event

- Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive